Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus FKUI 2021 per tanggal 31 Mei 2021 (358 artikel)
Publikasi Scopus FKUI 2021 per tanggal 31 Mei 2021 (358 artikel)
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model
2021
Pharmacogenomics Journal
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103643380&doi=10.1038%2fs41397-021-00225-9&partnerID=40&md5=927cb9a5fa739ff5a932d25eb4459bd0
Department of Pharmacology, Faculty of Medicine, YARSI University, Jakarta Pusat, Indonesia; Genetic Research Center, YARSI Research Institute, YARSI University, Jakarta Pusat, Indonesia; Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan, South Korea; Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, South Korea; Department of Pharmacology and Therapy, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia; Department of Pharmacology & Therapeutic, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia; Medical Genetics Section, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, United States; The Golden Helix Foundation, London, United Kingdom; Department of Pharmacy, University of Patras, Patras, Greece; Department of Pathology, United Arab Emirates University College of Medicine and Health Sciences, Al-Ain, United Arab Emirates; Department of Population Health Sciences, Geisinger, Danville, PA, United States; Genomic Medicine Institute, Geisinger, Danville, PA, United States; Health Policy & Behavioral Sciences, Georgia State University, Atlanta, GA, United States
Carbamazepine (CBZ)-induced Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are strongly associated with the HLA-B*15:02 allele. Screening HLA-B*15:02 before CBZ administration might prevent CBZ-induced SJS/TEN by enabling clinicians to prescribe alternative therapy for positive patients. Similar to other Southeastern Asian countries, HLA-B*15:02 is highly prevalent in Indonesia. Therefore, we assessed the economic value of HLA-B*15:02 screening before CBZ prescription to patients with epilepsy in Indonesia. A generic cost-effectiveness model and decision support tool, developed to enable users to perform an initial cost-effectiveness analysis from a healthcare provider/payer perspective, were used to assess the value of HLA-B*15:02 genotyping. The incremental cost-effectiveness ratio of adopting universal HLA-B*15:02 screening was 656,444,671 Indonesian Rupiah (IDR)/quality-adjusted life year (QALY) gained for patients compared with 2,634,975,574 IDR/QALY gained for providing valproic acid (alternative drug) without screening. Thus, neither HLA-B*15:02 screening nor substitution with VPA meets the Indonesian threshold for cost effectiveness. However, the improved outcomes with this test in other Asian countries may inform the desirability of implementation in Indonesia even with suboptimal cost-effectiveness. © 2021, The Author(s), under exclusive licence to Springer Nature Limited.
Springer Nature
1470269X
Article
Q1
981
4456